Anti-dsDNA

Anti-dsDNA Antibodies

Q: Does a positive anti-dsDNA mean I have lupus?

A positive anti-dsDNA is highly specific for SLE, particularly by Crithidia or Farr assay (>95% specificity), but it must be interpreted alongside clinical features. Anti-dsDNA alone is not diagnostic—SLE requires both serological and clinical criteria. Some other autoimmune conditions can occasionally produce low-level positive results, especially by ELISA.

Immune & Inflammation

What is Anti-dsDNA Antibodies?

Anti-double-stranded DNA (anti-dsDNA) antibodies are autoantibodies directed against the double-helical structure of native DNA. They are a hallmark serological marker of systemic lupus erythematosus (SLE) and are included in both the 2019 EULAR/ACR and the older 1997 ACR classification criteria for SLE. These antibodies belong predominantly to the IgG class and are thought to contribute directly to disease pathogenesis, particularly lupus nephritis, through immune complex deposition in the glomeruli.

Several laboratory methods are used to detect anti-dsDNA antibodies, each with different sensitivity and specificity profiles. The Farr assay (radioimmunoassay) and the Crithidia luciliae immunofluorescence test (CLIFT) are considered the most specific for SLE, though they are less sensitive. ELISA-based methods are more sensitive but less specific, potentially detecting antibodies against single-stranded DNA or other nuclear antigens. The choice of assay affects the clinical interpretation of results. Serial monitoring of anti-dsDNA titers is used to track SLE disease activity, as titers often rise during flares, particularly renal flares.

Why It Matters

Anti-dsDNA antibodies are highly specific for SLE (95–97% specificity by CLIFT or Farr assay), making them one of the most useful diagnostic markers. They are found in 60–70% of SLE patients at some point during their disease course. Rising anti-dsDNA titers often precede clinical flares, particularly lupus nephritis, and can prompt preemptive treatment intensification. Anti-dsDNA antibodies form immune complexes that deposit in the kidneys, skin, and joints, directly contributing to tissue damage. Their presence, especially at high titers, is associated with more severe disease, including proliferative glomerulonephritis.

Normal Reference Ranges

Group	Range	Unit
Adults (ELISA)	<30	IU/mL
Adults (CLIFT)	Negative
Adults (Farr assay)	<7	IU/mL

Reference ranges may vary by laboratory. Always compare results to the ranges provided by your testing facility.

What High Anti-dsDNA Levels Mean

Common Causes

Systemic lupus erythematosus (most specific association)
Lupus nephritis (correlates with renal disease activity)
Drug-induced lupus (rarely anti-dsDNA positive; more commonly anti-histone)
Mixed connective tissue disease (occasionally)
Autoimmune hepatitis (occasionally)

Possible Symptoms

Joint pain and swelling
Butterfly (malar) rash
Fatigue
Fever
Photosensitivity
Oral ulcers
Foamy urine or edema (if lupus nephritis)
Pleuritis or pericarditis

What to do: Elevated anti-dsDNA antibodies in the context of compatible clinical features strongly support a diagnosis of SLE. Check complement levels (C3, C4)—low complement with high anti-dsDNA suggests active disease and possible lupus nephritis. Urinalysis and urine protein-to-creatinine ratio should be assessed to evaluate for renal involvement. If lupus nephritis is suspected, renal biopsy may be needed for classification and treatment planning. Treatment is guided by organ involvement and may include hydroxychloroquine, corticosteroids, mycophenolate, or belimumab.

What Low Anti-dsDNA Levels Mean

Common Causes

Normal result—no autoantibodies detected
SLE in remission
Effective immunosuppressive therapy

Possible Symptoms

No symptoms associated with negative anti-dsDNA

What to do: Negative anti-dsDNA does not exclude SLE—approximately 30–40% of SLE patients are anti-dsDNA negative, particularly those with milder disease or predominantly cutaneous or musculoskeletal involvement. If clinical suspicion remains, test other SLE-associated antibodies (anti-Smith, anti-RNP, anti-Ro/SSA, anti-La/SSB). In known SLE patients, declining anti-dsDNA levels with treatment indicate improving disease activity.

When Is Anti-dsDNA Testing Recommended?

Suspected systemic lupus erythematosus (especially with positive ANA)
Monitoring SLE disease activity and predicting flares
Evaluating suspected lupus nephritis
Following response to immunosuppressive therapy in SLE

Frequently Asked Questions

A positive anti-dsDNA is highly specific for SLE, particularly by Crithidia or Farr assay (>95% specificity), but it must be interpreted alongside clinical features. Anti-dsDNA alone is not diagnostic—SLE requires both serological and clinical criteria. Some other autoimmune conditions can occasionally produce low-level positive results, especially by ELISA.

Yes, in SLE patients. Rising anti-dsDNA titers, especially when accompanied by falling complement (C3, C4), often precede clinical flares by weeks to months. Regular monitoring (every 3–6 months or more frequently during active disease) can help guide treatment decisions and enable preemptive therapy intensification.

Yes. Anti-dsDNA antibodies form immune complexes that deposit in the glomerular basement membrane and mesangium of the kidneys, activating complement and triggering inflammation (lupus nephritis). High titers of anti-dsDNA, particularly IgG subclass antibodies with high avidity for DNA, are strongly associated with proliferative glomerulonephritis, the most serious form of lupus kidney involvement.

Related Biomarkers

RFRheumatoid Factor ESRErythrocyte Sedimentation Rate

Want your Anti-dsDNA levels analyzed?

Upload your lab results for an instant AI-powered breakdown of all your biomarkers.

Upload Lab Results →

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reference ranges may vary between laboratories. Always consult your healthcare provider for interpretation of your specific test results.